＜135A＞ VRAIN 3460 -235
Low price since listing. While there are no noticeable transaction materials, sales are growing. It was newly listed on 2/22 and rose to 7890 yen at one point, but then it remained soft, and the public price (2990 yen) is perceived as an intention to lower the price. The main business is providing AI solutions for the manufacturing industry, and the operating profit forecast for the fiscal year ending 25/2 also temporarily became popular because good performance was expected to be 771 million yen, a 51.8% increase from the previous fiscal year, but it seems that sales dominance is developing due to short-term outflows of funds.
＜3680＞ Hotlink 314 49
High temporary stop. It has been announced that the group company US Effyis (service brand name is Socialgist) has concluded a strategic partnership with US Accern, a generative AI startup. SocialGist provides Accern with access rights to public conversational content repositories necessary for developing generative AI applications. Accern can now use over 35 billion public posts per year, such as news and blogs, and will be used to promote the development of generative AI applications.
＜9556＞ INTLOOP 3005 +55
Significant backlash. It has been announced that comprehensive collaboration in providing edge AI solutions and engineering support etc. will begin with Idein (Chiyoda-ku, Tokyo), which develops and operates edge AI platforms. As the first initiative, we will provide a new type of proof of concept (PoC) companion support service. Edge AI technology developed by IDEin and PoC solutions utilizing large-scale language models (LLM) are combined with Intloop consulting support services.
＜3133＞ Haifan 928 +84
A significant increase of 3 days. It has been announced that collection of loan funds has been completed from Meta Energy (Chiyoda-ku, Tokyo), which operates the photovoltaic power generation business. The total repayment amount is approximately 176 million yen in principal and interest, and it is planned to be used to acquire fixed assets related to the Group's renewable energy business. Also, in addition to partially changing the articles of incorporation and adding consulting services, etc. related to the establishment and operation of medical institutions as new business purposes, the total number of shares that can be issued will be expanded from 60.555,600 shares to 20,03075,600 shares.
＜4894＞ Qualips 5470 +250
The price has been high since listing. It has been announced that a doctor-led clinical trial for dilated heart disease, which Osaka University is proceeding with research and development as an addition to the efficacy of treatment using human iPS cell-derived cardiomyocyte sheets for ischemic heart disease, has begun, and Qualips has provided a cardiomyocyte sheet for the first case of transplantation. Research and development for dilated heart disease has been selected for the Reiwa 5 “Regenerative Medicine Practical Application Research Project” by the Japan Agency for Medical Research and Development (AMED).
＜6031＞ Signia 1075 +57
The price has been high since the beginning of the year. The year-end dividend forecast for the fiscal year ending 24/6 has been increased and revised from the previous 4.50 yen to 5.00 yen (5.00 yen for the previous fiscal year end results). Measures that take into account performance trends and the degree of fulfillment of internal reserves. Also, with 8/31 (effectively 8/30) as the reference date, it will be split at a ratio of 2 shares per share. The purpose is to reduce the amount of money per investment unit, improve stock liquidity, and expand the investor base. Since the effective date is 9/1, there is no impact on year-end dividends for the fiscal year ending 24/6.